Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis

ELCC 2025

Lung, Respiratory and Thoracic Cancer

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

Lung, Respiratory and Thoracic Cancer

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

Lung Cancer

Cho BC, Hayashi H, Lee JS, Lee SH, Danchaivijitr P, Cheng Y, Liu B, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yoshioka H, Nahit Şendur MA, Prabhash K, Azuma K, Lee YG, Lin CC, Matsumoto S, Sunpaweravong P, Xia Y, Martinez M, Bauml JM, Sethi S, Lu S

doi: 10.1016/j.lungcan.2025.108496

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

MARIPOSA Study: Frontline amivantamab plus lazertinib reduces acquired resistance versus osimertinib in patients with NSCLC harboring common EGFR mutations*

Lung, Respiratory and Thoracic Cancer

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Lung Cancer

Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, Thiagarajan M, Hung JY, Boyer M, Çİl T, Yao Y, Nagarkar R, Xie J, Bhattacharya A, Wortman-Vayn H, Baig M, Agrawal T, Lorenzini P, Lee SH, Cho BC

doi: 10.1016/j.lungcan.2026.109302

Lung, Respiratory and Thoracic Cancer

Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA

J Thorac Oncol

Lee SH, Lu S, Hayashi H, Felip E, Spira AI, Girard N, Kim YJ, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yang JC, Besse B, Thomas M, Shah S, Baig M, Curtin JC, Zhang J, Xie J, Sun T, Sethi S, Wang M, Fennema E, Daksh M, Ennis M, Bauml JM, Cho BC

doi: 10.1016/j.jtho.2025.06.030

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

Lung Cancer

Gomez-Randulfe I, Monaca F, Cantale O, Reale ML, Mrak L, Zullo L, Diaz SS, Bueno MZ, Maridueña Moreno MA, Davis C, Cox S, Lee D, Shah R, Geldart T, Baena J, Benitez JC, Rosario Garcia Campelo MA, Remon J, Planchard D, Galetta D, Tiseo M, Cortinovis D, Metro G, Bria E, Passiglia F, Novello S, Califano R

doi: 10.1016/j.lungcan.2025.108797

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Lung, Respiratory and Thoracic Cancer

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

Lung Cancer

Paz-Ares L, Veillon R, Majem M, Zhou C, Tang KJ, Kim SW, Richardson G, Girard N, Sanborn RE, Mansfield AS, Park K, Schuchard J, Diels J, Sermon J, Bhattacharya A, Lorenzini P, Wortman-Vayn H, Knoblauch RE, Agrawal T, Baig M, Ono A, Sabari JK

doi: 10.1016/j.lungcan.2025.108788

Lung, Respiratory and Thoracic Cancer

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients

Adv Ther

Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M

doi: 10.1007/s12325-025-03465-4

Related content

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

MARIPOSA Study: Frontline amivantamab plus lazertinib reduces acquired resistance versus osimertinib in patients with NSCLC harboring common EGFR mutations*

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients